Valuation: Interpace Biosciences, Inc.

Market Cap 35.84M 31.32M 29.44M 26.87M 50.42M 3.43B 50.43M 353M 136M 1.75B 135M 132M 5.64B P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 34.52M 30.17M 28.36M 25.88M 48.56M 3.3B 48.57M 340M 131M 1.69B 130M 127M 5.43B EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
8.77%
Yield 2024 *
-
Yield 2025 -
1 day+0.31%
1 week-0.46%
Current month-14.53%
1 month-15.02%
3 months-20.61%
6 months-23.88%
Current year+5.19%
1 week 6.45
Extreme 6.45
6.65
1 month 5.97
Extreme 5.9732
7.85
Current year 5.15
Extreme 5.15
12
1 year 3.85
Extreme 3.85
12
3 years 2.22
Extreme 2.216625
17.7
5 years 2.22
Extreme 2.216625
50.25
10 years 2.22
Extreme 2.216625
990
Manager TitleAgeSince
Chief Executive Officer 64 30/11/2020
Director of Finance/CFO 34 20/04/2023
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 79 20/06/2016
Director/Board Member 73 31/12/2015
Director/Board Member 64 21/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
20/08/26 Free

Director

69,252 0.2501%
20/08/26 Exercice

Chief Financial Officer

1,385,045 5.0015%
20/08/26 Free

Director

69,252 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
+0.31%-0.46%+57.75%+12.52% 35.84M
+5.47%+11.44%+118.15%+753.12% 56.35B
-2.94%-3.84%+11.70%+51.86% 25.27B
-0.63%-2.71%-13.90%-37.94% 6.72B
+1.73%-4.14%-2.26%+167.77% 5.82B
-0.70%-0.03%+13.82%+58.86% 3.34B
-7.19%-4.06%-30.04%+2,429.25% 2.71B
-2.68%0.00%+124.88%+55.47% 2.43B
+0.59%+3.90%+38.71%+48.59% 2.35B
+1.04%+8.03%-4.03%-53.41% 1.98B
Average -0.51%+0.89%+31.48%+348.61% 10.7B
Weighted average by Cap. +2.01%+4.94%+67.29%+480.29%

Financials

2024 2025
Net sales 46.93M 41.01M 38.54M 35.17M 66.01M 4.49B 66.02M 463M 178M 2.29B 176M 172M 7.39B 38.73M 33.84M 31.81M 29.03M 54.48M 3.7B 54.49M 382M 147M 1.89B 145M 142M 6.1B
Net income 6.7M 5.86M 5.5M 5.02M 9.43M 641M 9.43M 66.07M 25.49M 327M 25.17M 24.62M 1.05B 24.58M 21.48M 20.18M 18.42M 34.57M 2.35B 34.58M 242M 93.48M 1.2B 92.29M 90.27M 3.87B
Net Debt 4.4M 3.84M 3.61M 3.29M 6.18M 420M 6.18M 43.32M 16.72M 215M 16.5M 16.14M 692M -1.32M -1.16M -1.09M -991K -1.86M -126M -1.86M -13.03M -5.03M -64.54M -4.96M -4.86M -208M
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
22/09/26 US$6.470 +0.31% 1,489
18/09/26 US$6.450 0.00% 723
17/09/26 US$6.450 0.00% 170
16/09/26 US$6.450 -0.77% 512
15/09/26 US$6.500 +3.17% 676

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDXGD Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!